Reducing diagnostic delay for better cancer outcomes

Reducing diagnostic delay for better cancer outcomes

VJOncology

2 years
651 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Richard Neal, MB, ChB, PhD, FRCGP, from the Leeds Institute of Health Sciences, Leeds, UK, discusses his talk on reducing diagnostic delay for better cancer outcomes, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes that early diagnosis is associated with better cancer outcomes, and suggests that health care systems with a slower diagnosis process can learn from countries with faster diagnosis, resulting in better outcomes. Prof. Neal highlights three ways in which earlier diagnosis can be achieved. Firstly, patients should be encouraged to visit their healthcare practitioner when they display certain symptoms, such as coughing for three week. He points out the effectiveness of awareness campaigns in achieving short- and medium-term benefit, as these campaigns both educate about symptoms and indicate what should be done by the patient, but argues that awareness campaigns must be improved to derive long-term benefit, so that patients presenting with symptoms quickly access primary care services. Secondly, Prof. Neal talks about how the behavior of primary care practitioners can be changed to form a safety net, such as telling patients that they should return if they develop an additional symptom, as most cancers begin with symptoms which are common, for example stomach pain. Primary care practitioners should use decision support tools to enable effective identification of patients at risk of undiagnosed cancer, taking into account symptoms, risk factors, age, and patient group. Harnessing this technology will also allow them to work more efficiently. Finally, better tests need to be available and accessible to primary care practitioners to enable cancer diagnosis.
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 1 day
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 1 day
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 1 day
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 1 day
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 2 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 2 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 2 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days